ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research ...
ICON plc (NASDAQ:ICLR) traded sharply lower on Thursday, sparking a selloff among its rival contract research organizations after the Ireland-based company cut its guidance with its Q3 results. In ...
ICON plc ICLR is well-poised to grow in the upcoming quarters, driven by its strategic additions. Leveraging AI and technology advancements, the company is optimizing clinical delivery and has seen ...
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results